Biopharma expansion is turning into a location-led competition as capacity constraints outpace timelines for new GMP facility builds. The industry is prioritizing ‘ready-now’ sites—areas with GMP-capable infrastructure, utilities, and cold-chain logistics already in place—because greenfield capacity typically arrives on multi-year cycles. A concrete example cited is Middlesex County, New Jersey, which has invested in the ecosystem needed to move from planning to production quickly. The coverage ties local advantages to speed-to-operation, proximity to major ports and airports, and access to a regulatory-grade talent pool. The piece underscores that talent density and GMP-fluent staffing are acting as bottlenecks alongside physical capacity, with the county highlighted for unusually high pharmaceutical manufacturing employment and advanced-degree levels.